IMNM Forensic analysis

• >Thesis: IMNM is a well-capitalized biotech with a near-term catalyst (Varegacestat NDA under review) and a deep ADC pipeline. The stock is in a short-term pullback within a larger, structurally bullish uptrend, offering an attractive entry point.
• >Entry Zone: $20.25 - $21.50. Accumulate on weakness into this zone, which aligns with the lower Bollinger Band and the rising 10-day SMA.
• >Scaling Strategy:
  • >Initial Entry (30%): Enter at $21.50 (test of 10-day SMA).
  • >Add (40%): Add at $20.50 (if it pulls back towards the lower Bollinger Band).
  • >Final Add (30%): Reserve final tranche for a potential dip to psychological support at $19.75.
• >Stop Loss: Hard stop at $18.45. This is decisively below the 200-day SMA ($18.72), which is the key long-term support level.
• >Take Profit Levels:
  • >PT1: $24.00 (Upper Bollinger Band / recent resistance). Sell 30% of the position.
  • >PT2: $27.50 (Next resistance level). Sell another 40% of the position.
  • >PT3: Let the remaining 30% run to a longer-term target of $30.00+, anticipating positive pipeline news or progress on the Varegacestat review.
• >Position Sizing: 3% - 5% of portfolio, given the binary risk profile inherent in biotech.
• >Risk/Reward Ratio: Based on an average entry of $20.80, the R/R to PT2 is approximately 1:2.85 (Risk: $2.35/share, Reward: $6.70/share).
• >Maximum Hold Time: 4-6 weeks for the swing trade portion. Can be converted to a longer-term position if the thesis remains intact and price action is constructive.
• >Catalyst Timing: Enter before any major pipeline data releases. The primary catalyst, the Varegacestat PDUFA date, is expected in early 2027, making this a swing trade with a long-term catalyst backstop.

Immunome, Inc. (IMNM) is a well-capitalized clinical-stage biotech focused on oncology. As of 2026-06-01, the company has a strong balance sheet with $582.7M in cash, a lead asset (Varegacestat) with an NDA filed and under FDA review, and a deep pipeline of promising ADC candidates. The current stock price of $21.83 reflects a short-term pullback within a long-term uptrend, presenting a favorable entry for a techno-fundamental swing trade.

No critical 8-K filings were noted in the provided data. The most significant recent corporate event is the submission of the New Drug Application (NDA) for Varegacestat in April 2026, as disclosed in the 10-Q.

• >The Q1 2026 10-Q filing notes the exercise of 38,197 stock options. This is routine and not a significant signal.
• >No recent open-market insider buying or selling (Form 4) data was provided for this analysis. The absence of heavy insider selling ahead of catalysts is a mild positive.

• >Varegacestat NDA Submission (April 2026): This is the most critical near-term driver. The submission follows positive Phase 3 data for desmoid tumors. A standard 10-month review would place a potential PDUFA decision date in February 2027. This creates a clear catalyst path for the next 8-10 months.
• >Deepening Pipeline: The company plans to initiate a Phase 1 trial for IM-1617 in Q2 2026 and expects to submit two more INDs for other ADC assets (IM-1340 and IM-1335) in mid and late 2026. This continuous news flow can provide additional support for the stock.
• >Competitive Landscape: SpringWorks Therapeutics' competing drug, OGSIVEO, was approved in November 2023. While this validates the mechanism of action, it also presents a commercial competitor. IMNM will need to demonstrate a competitive profile.

• >Revenue Mix: IMNM is a pre-commercial biotech. It currently generates no recurring revenue. Its prior collaboration revenue from AbbVie ended in July 2025.
• >Primary Value Driver: The business model is focused on developing and commercializing a portfolio of targeted oncology therapies. Value is driven by achieving clinical milestones, regulatory approvals, and eventual product sales.
• >Key Assets: The pipeline is led by Varegacestat (a small molecule GSI) and followed by a deep pipeline of proprietary Antibody-Drug Conjugates (ADCs), including IM-1021, IM-3050, and IM-1617.

Insight: The balance sheet is a fortress for a company of this size, providing a multi-year cash runway that significantly de-risks the operational side of the business leading into key catalysts.

• >Cash Position: $582.7M in cash and cash equivalents as of March 31, 2026.
• >Debt: Minimal liabilities of $31.1M. The company has no significant debt.
• >Cash Burn: Net cash used in operations was $58.6M in Q1 2026. This implies an annual burn rate of approximately $234M.
• >Runway: At the current burn rate, the company has a cash runway of approximately 2.5 years, sufficient to fund operations well past the anticipated Varegacestat PDUFA date and through multiple other clinical milestones.

• >Market Cap: $2.47B (at $21.83/share)
• >Enterprise Value (EV): $1.92B (Market Cap - Net Cash)
• >Reverse DCF / Implied Value: The $1.92B EV suggests the market is pricing in a significant probability of success for Varegacestat and assigning early-stage value to the ADC platform. Given that a successful desmoid tumor drug could achieve peak sales of $500M - $1B, a 3-4x peak sales multiple would imply a value of $1.5B - $4.0B for Varegacestat alone. The current EV is within this range, suggesting the market is somewhat optimistic but leaves substantial upside if Varegacestat is approved and the ADC pipeline delivers positive data.
• >Asymmetry: The risk/reward appears favorable. A regulatory failure could cut the stock price by 50%+, while a successful approval and launch could drive the stock towards the $30-$40 range over the next 12-18 months.

• >Varegacestat: Competes directly with SpringWorks' (now Merck KGaA) OGSIVEO, which is already approved. IMNM will need to differentiate on efficacy, safety, or tolerability to capture significant market share.
• >ADC Platform: The oncology ADC space is highly competitive, with major players like Pfizer (via Seagen), AstraZeneca/Daiichi Sankyo, and AbbVie (via Immunogen). IMNM's strategy of targeting novel or underexplored targets is a key differentiator, but execution is paramount.

Management has a track record of advancing assets through clinical development and executing strategic transactions, including the key acquisitions that built the current pipeline. The team's ability to raise nearly $600M in 2025 demonstrates strong capital markets execution. Their focus on building a multi-asset pipeline shows strategic foresight.

• [CRIT]Regulatory Risk: The primary risk is the FDA's decision on the Varegacestat NDA. A Complete Response Letter (CRL) or rejection would be a major negative catalyst.
• [WARN]Competition Risk: Varegacestat faces an entrenched competitor. Even with approval, commercial uptake is not guaranteed.
• [WARN]Clinical Trial Risk: The ADC pipeline is promising but early-stage. Any setbacks in Phase 1/2 trials for assets like IM-1021 or IM-1617 would negatively impact the long-term valuation.
• [WARN]Dilution Risk: While well-funded now, the company has a history of raising capital through equity offerings. Future development will require more capital, leading to potential dilution in the long term.

• [WARN]Share-Based Compensation: SBC was $8.0M in Q1, representing 13.5% of total operating expenses. While not extreme for biotech, it is a notable non-cash expense to monitor.
• >Historical Dilution: Shares outstanding grew ~42% YoY due to large capital raises in 2025. While necessary to fund the company, this is a significant level of dilution that shareholders have absorbed.

Insight: The technical picture is classic 'bullish consolidation'. The price is pulling back in an orderly fashion after a strong run, holding well above its long-term trend indicator (200-day SMA). This is an ideal setup for accumulating a position on weakness.

• >Trend: The long-term trend is BULLISH, with the price +16.63% above the 200-day SMA ($18.72). The short-term trend is a BEARISH/NEUTRAL consolidation, with the price currently below the 5-day SMA ($22.01) and 50-day SMA ($22.14).
• >Momentum: NEUTRAL. RSI is 48.17, indicating the stock is neither overbought nor oversold. MACD has a slight bullish signal, suggesting the recent downward momentum may be waning.
• >Key Levels:
  • >Support: $20.13 (Lower Bollinger Band), $18.72 (200-day SMA - CRITICAL SUPPORT).
  • >Resistance: $22.14 (50-day SMA), $24.07 (Upper Bollinger Band).
• >Reconciliation: The strong fundamental story (cash, catalysts) is supported by a bullish long-term technical trend. The current short-term weakness provides a tactical entry opportunity rather than a signal of a broken thesis. This is not a value trap.

This setup is better suited for a multi-week swing, but a short-term trade is viable if it reclaims key levels.

• >Recommended Timeframe: Swing Trade (2–5 Days) to Swing Trade (1–2 Weeks).
• >Setup: Look for a bounce off the $21.50 level or a close back above the 50-day SMA at $22.14.
• >Position Sizing: 2% of portfolio for a short-term trade.
• >Entry: Enter 50% at $21.50 and the other 50% on a confirmed close above $22.20.
• >Take Profit: Target $23.50 - $24.00.
• >Stop Loss: A tight stop at $20.90 (below the recent swing low).
• >Risk/Reward: Approx 1:3.

A short position is NOT recommended at this time due to the strong fundamental backdrop and bullish long-term trend. This setup violates the "Widowmaker" Rule; shorting a fundamentally strong company on a minor pullback is a low-probability trade. A valid short thesis would only emerge upon:

• >Bear Trigger: A definitive rejection of the Varegacestat NDA by the FDA, or a major safety issue in a key ADC trial.
• >Technical Breakdown: A sustained break below the 200-day SMA at $18.72 on high volume would signal a major trend change.

• >Mid-2026: IND submission for IM-1340.
• >Late 2026: IND submission for IM-1335.
• >Throughout 2026: Initial clinical data for IM-1021 (lymphoma).
• >End of 2026: Planned MAA submission in Europe for Varegacestat.
• >Q1 2027 (est.): Potential PDUFA decision date for Varegacestat in the U.S.

BUY with a High Conviction score of 8/10.

IMNM represents a compelling techno-fundamental opportunity. The company is financially robust, mitigating near-term financing risk. It has a clear, high-impact catalyst with the Varegacestat NDA review. The stock's technical posture—a healthy pullback within a confirmed uptrend—provides an attractive entry point for a position ahead of anticipated news flow and value creation events.

IMNM presents a compelling techno-fundamental long setup: a well-capitalized biotech with a de-risked lead asset and a deep pipeline, currently experiencing a buyable technical pullback to key support levels ahead of major catalysts.